BioPharmSignal logoBioPharmSignal

Biotech News

Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026

Immuneering (IMRX)ImmuneeringCompany update

- Durable complete regressions observed in 50% of mice in a RAS-mutant colorectal cancer model treated with Atebimetinib plus anti-PD-1, with no regrowth even after dosing stopped - - Median survival extended by 1.8-fold with atebimetinib plus anti-PD-1 and chemotherapy versus anti-PD-1 plus

Related news

IMRXImmuneering2026-11-04 12:30 EST

Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium

IMRXImmuneering2026-10-02 13:00 EST

Immuneering to Present at the 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC)

IDYAIDEAYA Biosciences2026-10-23 10:00 EST

IDE849 (SHR-4849) DLL3 TOP1 ADC Updated Phase 1 Results at ESMO 2026 Demonstrates Promising Anti-Tumor Activity and Preliminary Overall Survival Results in Relapsed Small Cell Lung Cancer and Neuroendocrine Carcinomas

BMYBMYBristol-Myers Squibb Company2026-10-26 07:30 EST

Izalontamab Brengitecan (Iza-Bren) Doubles Median Progression-Free Survival in Patients with Previously-Treated EGFR-Mutated Non-Small Cell Lung Cancer Compared to Chemotherapy in the Phase 3 PANKU-Lung01 Study

ZNTLZentalis2026-10-23 14:15 EST

Zentalis Pharmaceuticals Announces Meaningful Median Overall Survival Data in Cyclin E1-Positive Platinum-Resistant Ovarian Cancer from DENALI Part 1b to be Presented at the ESMO Congress 2026

RVMDRevolution Medicines2026-10-20 12:00 EST

Revolution Medicines Begins Treating Patients in Phase 3 RASolve 308 Trial Evaluating Zoldonrasib in Combination with Pembrolizumab and Chemotherapy as First-Line Treatment for Patients with Metastatic RAS G12D Non-Squamous Non-Small Cell Lung Cancer

REGNRegeneron Pharmaceuticals2026-10-25 09:15 EST

Libtayo® (cemiplimab) Longer-Term Data Show Increasing and Clinically Meaningful Overall Survival Benefit with Adjuvant Treatment in High-Risk Cutaneous Squamous Cell Carcinoma (CSCC)

RVMDRevolution Medicines2026-10-23 11:30 EST

Revolution Medicines Presents Overall Survival Data for RASONQUE™ (daraxonrasib) Across Subgroups in Previously Treated Metastatic Pancreatic Cancer at ESMO 2026

CHRSCoherus BioSciences, Inc.2026-10-28 20:05 EST

Coherus Oncology Announces Compelling Tagmokitug Interim Clinical Data in Esophageal Cancer and Path to Advance Development

BNTXBioNTech2026-10-26 09:00 EST

BioNTech and DualityBio Announce Topline Results of the DYNASTY-Breast02 Global Phase 3 Clinical Trial Evaluating Trastuzumab Pamirtecan in HR+/HER2-low Metastatic Breast Cancer

View all latest news

Immuneering

Deep Cyclic Inhibitors Immuneering is a late-stage clinical oncology company developing Deep Cyclic Inhibitors for RAS-, RAF- and other MAPK-driven cancers. The approach is designed to produce durable pathway inhibition while limiting resistance, cachexia and treatment-related toxicity. Atebimetinib Atebimetinib is an oral, once-daily...

Recent company news

IMRXImmuneering2026-11-06 14:00 EST

Atebimetinib Combinations with Anti-PD1 Cured 50% of Mice in a RAS-Mutant Colorectal Cancer Model and Nearly Doubled Survival in a RAS-Mutant Lung Cancer Model; New Data Presented at SITC 2026

IMRXImmuneering2026-11-04 21:05 EST

Immuneering to Present at the Guggenheim 3rd Annual Healthcare Innovation Conference

IMRXImmuneering2026-11-04 12:30 EST

Immuneering to Highlight Atebimetinib’s Broad Potential for Combinations in Pancreatic and Anaplastic Thyroid Cancers at the 2026 EORTC-NCI-AACR Symposium

IMRXImmuneering2026-10-29 20:05 EST

Immuneering Reports Third Quarter 2026 Financial Results and Provides Business Updates

IMRXImmuneering2026-10-26 11:30 EST

Immuneering Presents Design and Methodology of Ongoing Phase 3 MAPKeeper 301 Trial at ESMO Congress 2026

Stock data

Close
3.37 USD
Market cap
276.9M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States